Comparison of intravitreal ranibizumab injection with or without tissue plasminogen activator in the treatment of type 2 choroidal neovascularization

Comparison of intravitreal ranibizumab injection with or without tissue plasminogen activator in the treatment of type 2 choroidal neovascularization - Effect of tissue plasminogen activator on type 2 choroidal neovascularization

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000017081

Enrollment

Registered

2015-04-10

Start date

2010-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neovascular age-related macular degeneration

Interventions

intravitreal injection of tPA combined with intravitreal ranibizumab intravitreal ranibizumab

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Age related macular degeneration with type 2 choroidal neovascularization,

Exclusion criteria

Exclusion criteria: previous treatments involving laser photocoagulation or photodynamic therapy

Design outcomes

Primary

Measure	Time frame
Best-corrected visual acuities (BCVAs)	—

Secondary

Measure	Time frame
Central retinal thickness Macular volume The ILM-RPE thickness at the thickest point of the subretinal fibrinous and/or fibrovascular tissues	—

Countries

Japan

Contacts

Public ContactTsutomu Yasukawa

Nagoya City University Graduate School of Medical Sciences Department of Ophthalmology and Visual Science

yasukawa@med.nagoya-cu.ac.jp052-853-8251

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026